Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Packaging Corporation of America (PKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Packaging Corporation of America — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Packaging Corporation of America trades at $225.58 (market cap $20.71B). The key difference: Packaging Corporation of America is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap, and Packaging Corporation of America pays a 2.58% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PKG | |
|---|---|---|
Market Cap | $4.49B | $20.71B |
Sector | Health | Technology |
52-Week High | $28.06 | $246.31 |
52-Week Low | $20.06 | $191.41 |
Enterprise Value | $3.69B | $24.53B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Packaging Corporation of America (PKG) trades at $236.39, down 0.76% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported a Q1 2026 EPS beat of $2.40 versus $2.14 expected, with revenue growth to $2.4 billion. Recent news highlights a 20% dividend increase to an annual $6.00 per share and upcoming Q2 2026 earnings call on July 23, 2026.
PKG presents a mixed outlook with strong profitability metrics like a 16.21% ROE and 8.04% net margin, but faces margin pressure and two recent earnings misses. The consensus price target of $245 suggests modest upside, though risks include input cost inflation and competitive pressures. Institutional sentiment is cautiously optimistic with 38% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
